AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay

Less than a week after the FDA reserved judgment on Merck and AstraZeneca’s Lynparza as a treatment for metastatic castration-resistant prostate cancer (mCRPC), Europe has signed off on its use in the same indication.